Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2024 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.16367
Abstract: AIMS To examine the cost-effectiveness of first-line systemic therapies recommended by the National Comprehensive Cancer Network guidelines for Unresectable Hepatocellular Carcinoma (uHCC) from the US social and payer's perspective. METHODS A cost-effectiveness analysis was conducted… read more here.
Keywords: cost; cost effectiveness; line systemic; first line ... See more keywords
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13769
Abstract: This retrospective chart review examined real‐world healthcare resource utilization (HRU) in patients with AML ineligible for intensive therapy who received first‐line systemic therapy or best supportive care (BSC). read more here.
Keywords: best supportive; line systemic; ineligible intensive; first line ... See more keywords
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of gastroenterology and hepatology"
DOI: 10.1111/jgh.16225
Abstract: BACKGROUND AND AIM The study goal was to compare the outcomes of patients with unresectable hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) as either first- or later-line systemic therapy. METHODS A total of… read more here.
Keywords: later line; line systemic; first line; therapy ... See more keywords
Efficacy and safety of radiotherapy to delay second-line systemic therapy in patients with oligoprogressive hepatocellular carcinoma: study protocol of a multicentre, single-arm, phase II trial
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359251334538
Abstract: Background: Hepatocellular carcinoma (HCC) is a highly aggressive cancer with a paucity of efficacious treatment options, particularly in advanced stages following first-line systemic therapy (FLST). Objectives: The objective of this trial is to assess the… read more here.
Keywords: single arm; multicentre single; trial; patients oligoprogressive ... See more keywords
Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cancer"
DOI: 10.1186/s12885-024-12662-3
Abstract: To evaluate the safety of first-line systemic therapy for metastatic colorectal cancer through network meta-analysis. The literature from PubMed, Embase, Web of Science, and Cochrane Library databases was searched from the inception of the databases… read more here.
Keywords: colorectal cancer; cancer; metastatic colorectal; line systemic ... See more keywords
Predictors of first line systemic therapy for metastatic renal cell carcinoma in IMDC favorable risk patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e17086
Abstract: e17086Background: With the induction of molecular targeted agents, which interfere with proteins that play critical roles in tumor growth and progression, and immune checkpoint inhibitors (ICI), th... read more here.
Keywords: predictors first; therapy metastatic; first line; systemic therapy ... See more keywords
The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.719650
Abstract: Background The optimal second-line systemic treatment model for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains controversial. A Bayesian network meta-analysis (NMA) was performed to address this issue with regard to… read more here.
Keywords: line; line systemic; treatment; optimal second ... See more keywords
Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond.
Sign Up to like & getrecommendations! Published in 2020 at "Current oncology"
DOI: 10.3747/co.27.7103
Abstract: Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. It has a high mortality rate, especially when localized treatments fail. For about a decade, the only systemic treatment shown to improve… read more here.
Keywords: systemic treatment; hepatocellular carcinoma; line; line systemic ... See more keywords
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2021 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v27.i19.2415
Abstract: BACKGROUND The majority of clinical trials of first-line systemic treatments for hepatocellular carcinoma (HCC) used placebo or sorafenib as comparators, and there are limited data providing a cross comparison of treatments in this setting, especially… read more here.
Keywords: hepatocellular carcinoma; bevacizumab; randomized controlled; line ... See more keywords